
Terrie Curran, Phathom Pharmaceuticals CEO (Arcutis)
Phathom Pharmaceuticals resubmits NDA for acid blocker, bags $130M+ from offering
Phathom Pharmaceuticals is making another run at getting a green light to add two new indications for its drug vonoprazan while pricing a public offering to bring in $130.7 million, the company announced today.
In February, the FDA sent the company complete response letters for its erosive esophagitis NDA and H. pylori post-approval supplement to “address specifications and controls for a nitrosamine drug substance related impurity, N-nitroso-vonoprazan.”
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters